科斯特利奥 HTK 与普利戈索尔的对比：使用未成熟（H9C2）和成熟（HCM）心肌细胞培养物的体外比较。

Custodiol HTK versus Plegisol: in-vitro comparison with the use of immature (H9C2) and mature (HCM) cardiomyocytes cultures.

机构信息

Clinical Department of Cardiac Surgery, Wroclaw Medical University, Wroclaw, Poland.

Doctoral School, Wroclaw Medical University, Wroclaw, Poland.

出版信息

BMC Cardiovasc Disord. 2022 Mar 17;22(1):108. doi: 10.1186/s12872-022-02536-6.

DOI:10.1186/s12872-022-02536-6

PMID:35296256

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8928626/

Abstract

BACKGROUND

Although cardioplegia is used since the '70s of the last century, debate on cardioprotection during cardio-surgical procedures is still actual. The selection of a particular method depends mainly on the preferences and experience of a specific center or even surgeon. Crystalloid cardioplegia is an aqueous ion solution similar to intracellular (Custodiol HTK) or extracellular (Plegisol) fluid. The potensional clinical advantages of relatively new idea of cardioplegia solution based on intracellular composition (Custodiol HTK) justifies futher research, but only a few used cultured cells in laboratory conditions.

METHODS

In this study, the authors sought to compare Custodiol HTK with Plegisol cardioplegia solutions using an in-vitro model simulating cardioplegic arrest. The efficacy of myocardial protection during ischemia was investigated with susceptible indicators like the appearance of the deleterious effect of reactive oxygen species and oxidative stress markers. Immersed human cardiomyocytes and rat cardiomyoblasts H9C2 in cardioplegia for 4 h were examined for expression of oxidative stress markers (MnSOD, iNOS, HSP27), cardioplegic solutions cytotoxicity, and peroxidation damage of the cell's lipids and proteins. All tests were performed after 0.5 h, 1 h, 2 h, and 4 h of incubation in identical physical and biological conditions, which is difficult to achieve in clinical trials.

RESULTS

The lower cytotoxicity index performed on matured cells of human cardiomyocytes and highest dehydrogenase level showed after incubation with Custodiol HTK. This did not apply to tests on immature cells H9C2. Custodiol HTK induced significantly stronger iNOS expression. The decrease of HSP27 concentration has been instantaneous and maintained troughout the study only in both cultures incubated with Custodiol HTK. The other tests: lipid peroxidation, carbonyl groups concentration and MnSOD expression show no clear superiority evidence of used cardioplegic solutions.

CONCLUSIONS

Considering proceeded examinations on cultured cardiomyocytes, Custodiol HTK appears to be safer than Plegisol.

摘要

背景

尽管心脏停搏液自上世纪 70 年代以来一直在使用，但关于心脏手术过程中心脏保护的争论仍然存在。选择特定方法主要取决于特定中心甚至外科医生的偏好和经验。晶体心脏停搏液是一种类似于细胞内（Custodiol HTK）或细胞外（Plegisol）液的水性离子溶液。基于细胞内组成的相对较新的心脏停搏液概念的潜在临床优势（Custodiol HTK） justifies futher 研究，但只有少数实验室条件下使用培养细胞。

方法

在这项研究中，作者试图使用模拟心脏停搏的体外模型比较 Custodiol HTK 与 Plegisol 心脏停搏液。使用敏感指标（如活性氧物质和氧化应激标志物的有害作用的出现）研究缺血期间心肌保护的效果。将浸泡在心脏停搏液中的人心肌细胞和大鼠心肌细胞 H9C2 置于心脏停搏液中 4 小时，检查氧化应激标志物（MnSOD、iNOS、HSP27）的表达、心脏停搏液的细胞毒性以及细胞脂质和蛋白质的过氧化损伤。所有测试均在相同的物理和生物学条件下孵育 0.5、1、2 和 4 小时后进行，这在临床试验中很难实现。

结果

成熟的人心肌细胞的细胞毒性指数较低，与人成熟的心肌细胞孵育后脱氢酶水平最高的是 Custodiol HTK。这不适用于对未成熟细胞 H9C2 的测试。Custodiol HTK 诱导的 iNOS 表达明显更强。HSP27 浓度的降低是瞬时的，仅在与 Custodiol HTK 孵育的两种培养物中贯穿整个研究过程中保持不变。其他测试：脂质过氧化、羰基浓度和 MnSOD 表达没有明显证据表明使用的心脏停搏液具有优势。